Please assess the completion status of the following clinical trial:

Trial Title: Understanding Hemophilia A and B Drug Dosage Administration Patterns

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Physician/Clinician Participants:~* Must be a healthcare provider~* Currently manages at least 10 hemophilia A and/or B patients~Patient Participants:~* Willing and able to provide informed consent~* Diagnosed with hemophilia A or B~* Current disease severity is either moderately severe or severe with a clotting factor level of ≤5%~* If suffering from hemophilia A, must be currently taking moroctocog alfa (or another standard half-life treatment), rurioctocog alfa or efraloctocog alfa for at least six months.~(If currently taking rurioctocog alfa or efraloctocog alfa, must have been switched from a standard half-life treatment and had been on that prior treatment for at least six months).~* If suffering from hemophilia B, must be currently taking nonacog alfa or eftrenonacog alfa for at least six months (If currently taking eftrenonacog alfa, must have switched from nonacog alfa and had been on that prior treatment for at least six months).~* Infuse at least 3 times per month~Exclusion criteria:~* Female with hemophilia A or B~* Mild Haemophilia A or B

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemophilia B (Type: None): real world administration patterns and resource utilization implications
- Hemophilia A (Type: None): real world administration patterns and resource utilization implications

Based on this trial design, predict the completion outcome and termination type (if applicable).